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Risk of Lymphoma Following Exposure to Calcineurin
Inhibitors and Topical Steroids in Patients with Atopic
Dermatitis
Felix M. Arellano1,2,3, Charles E. Wentworth1, Alejandro Arana3, Carlos Ferna´ndez4 and Carle F. Paul5,6
Systemic use of immunosuppressant agents increases the risk of lymphoma in transplantation. We performed a
nested case–control study in the PharMetrics database to evaluate the association between topical
immunosuppressants and lymphoma in a cohort of patients with atopic dermatitis. We identified cases of
lymphoma and randomly selected four controls for each case, matched by length of follow-up. We used
conditional logistic regression to calculate odds ratio (OR) and 95% confidence intervals (CIs) of the association
between topical immunosuppressants and lymphoma. Two hundred and ninety-four cases of lymphoma
occurred in 293,253 patients, 81 in patients younger than 20 years. The adjusted analysis yielded the following
OR (95%CI) for: severity (OR 2.4; 95% CI 1.5–3.8), oral steroids 1.5 (1.0–2.4), ‘‘super potent’’ topical steroids 1.2
(0.8–1.8) , ‘‘low potency’’ topical steroids OR 1.1 (0.7–1.6); pimecrolimus 0.8(0.4–1.6), tacrolimus OR 0.8 (0.4–1.7),
and concomitant topical steroids, pimecrolimus, and tacrolimus 1.0 (0.3–4.1). We did not find an increased risk of
lymphoma in patients treated with topical calcineurin inhibitors. It is difficult to disentangle the effects of
severity of disease on outcome versus the true effects of drugs. However, in the adjusted analysis, severity of AD
was the main factor associated with an increased risk of lymphoma.
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INTRODUCTION
The prevalence of atopic dermatitis (AD) in Western
countries has increased over the last 30 years (Fleming
et al., 2001). AD affects approximately 20% of children and
1–3% of adults in developed countries (Williams et al., 1999).
Patients suffer from itch, loss of sleep, bleeding from the skin
and skin infection, and the disease also influences patients’
families (Su et al., 1997). AD is primarily a childhood disease
but persists through adulthood in up to 50% of cases
(Williams, 1997). For many patients with AD, intermittent
treatment with topical immunomodulatory drugs, that is,
topical corticosteroids or topical calcineurin inhibitors, is
necessary for disease control.
In the USA the incidence of lymphoma ranges from
around one case per 100,000 persons in children aged 0–19
years to 54 cases per 100,000 in patients over age 50
(Surveillance, Epidemiology, and End Results (SEER) Program.
http://www.seer.cancer.gov. Last accessed 16 April 2006).
Systemic use of immunosuppressive agents increases the risk
of lymphoma, especially after transplantation (Opelz and
Henderson, 1993). The risk of lymphoma in patients under-
going organ transplantation is closely related to the intensity
of immunosuppression (i.e., number and dose of immuno-
suppressive agents used) and ensuing inability to control
Epstein–Barr virus infection by the immune system (Opelz
and Do¨hler, 2003). Cases of immunosuppression-related
lymphoma have specific features: they are generally B-cell
non-Hodgkin lymphoma (NHL), may present as nodal or
extra-nodal tumors and may occur in unusual locations. They
are frequently polymorphic and may demonstrate clonal
integration of Epstein–Barr virus genome in malignant cells
(Liebowitz, 1998). The majority of immunosuppression-
related lymphoma develops within the first 2 years after
transplantation (Opelz and Do¨hler, 2003).
Any association between AD and lymphoma irrespective
of treatment is unclear. Some authors have found an
increased risk of hematological malignancies in patients with
eczema (Gibson et al., 1976; Bernard et al., 1984; Linet et al.,
1986; Cartwright et al., 1988; Eriksson et al., 1995). On the
other hand, at least two studies have observed that
eczema decreases the risk of NHL (Bernstein and Ross,
1992; Fabbro-Peray et al., 2001). Recently So¨derberg et al.
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(2004) found an association between ‘‘eczema’’ during
childhood and NHL in adulthood yielding a relative risk
(RR) of 2.3; (95% confidence interval (CI) 1.0–5.3) (So¨derberg
et al., 2004). Zhang et al. (2004) found an increased odds
ratio (OR) of T-cell NHL among women with eczema (OR
2.5; 95% CI 1.1–5.7) (Zhang et al., 2004).
Since December 2000 and December 2001, respectively,
two topical calcineurin inhibitors (tacrolimus ointment and
pimecrolimus cream) are available for the treatment of AD in
the USA; the drugs are also available in other regions of the
world. Long-term continuous application of tacrolimus
ointment and pimecrolimus in an experimental ethanol
solution to the skin of mice was associated with the
development of lymphoma. This occurred at 26- and 47-fold
higher exposures, measured by the area under the curve,
respectively than the maximum individual exposure ever
measured in humans after topical treatment (http://www.
pharma.us.novartis.com/product/pi/pdf/elidel.pdf. Last vis-
ited on 16 April 2006). The clinical relevance of the animal
findings is uncertain because the skin of mice is more
permeable than that of humans and high systemic exposure
following topical application in rodents has been documen-
ted whereas exposure in humans after topical application of
calcineurin inhibitors is minimal (Harper et al., 2005; Paul
et al., 2006). During post-marketing surveillance of topical
tacrolimus and pimecrolimus, cases of lymphoma have been
reported in patients treated with topical calcineurin inhibitors
used alone or in combination with topical corticosteroids
(Ormerod, 2005).We performed a case–control study to
assess the risk of lymphoma associated with the use of
topical prescription treatments for AD.
RESULTS
Description of the AD cohort
There were 293,253 patients of whom 171,724 (58.6%) were
o20 years old (Table 1). Most patients (75.4%) were enrolled
in the database from 2001 onwards. Almost 60% were female
subjects. AD was mainly diagnosed by a family physician,
pediatrician, or dermatologist. Twenty percent of patients met
the definition of severe.
The OR (95% CI) for each of the covariates on the risk of
lymphoma are shown on Table 2. Twenty-five percent of
patients used topical steroids at AD index date compared to 3
and 1.5% using pimecrolimus and tacrolimus, respectively.
Table 1. Characteristics of the study subjects
Characteristics of the study subjects N %
Age (yrs)
0–2 53,939 18.4
3–5 32,163 11.0
6–10 40,905 13.9
11–20 47,251 16.1
21–30 24,078 8.2
31–40 32,175 11.0
41–50 33,668 11.5
51–60 24,249 8.3
61+ 4,825 1.6
293,253 100.0
Sex
Males 124,765 42.5
Females 168,488 57.5
Table 1. continued
Characteristics of the study subjects N %
Entry period
o1997 260 0.1
1997–1999 27,554 9.4
2000–2002 151,993 51.8
2003–2004 113,167 38.6
42004 279 0.1
Region (USA)
East 87,064 29.7
Midwest 111,014 37.9
South 52,488 17.9
West 42,687 14.6
Physician specialty at index date
Family/general practice 61,349 20.9
Pediatrics 79,728 27.2
Dermatology 86,285 29.4
Allergy 15,096 5.1
Hematology 28 0.0
Hematology/oncology 131 0.0
Neonatal 1,165 0.4
Other 49,411 16.8
Unknown 2,148 0.7
Presence of infectious mononucleosis
Anytime in baseline 1,287 0.4
In follow-up period 1,037 0.4
Anytime in baseline or follow-up 2,259 0.8
Presence of asthma as comorbidity
Anytime in baseline or follow-up 50,794 17.3
Use of medications at index date1
Asthma 16,159 5.5
Oral steroids 14,762 5.0
Severity of AD
Not severe 235,689 80.4
Severe (among pts 0–2 yrs old) 10,804 3.7
Severe (among pts 3+yrs old) 46,760 15.9
pts, patients; yrs, years.
1Concomitant medications are defined as those having a prescription
date+days supplied+a 30-day buffer that includes the index date.
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Table 2. Risk of lymphoma in AD patients (OR; 95% CI)1
Characteristics of the study subjects Cases Controls OR 95% CI
Age group at lymphoma date, year
0–2 24 181 1.00
3–5 17 142 0.94 0.48 1.82
6–10 10 161 0.48 0.22 1.03
11–20 30 197 1.18 0.66 2.11
21–30 11 85 0.99 0.46 2.13
31–40 31 134 1.67 0.93 2.99
41–50 65 135 3.67 2.17 6.23
51–60 74 118 4.75 2.79 8.10
61+ 32 23 9.67 4.74 19.72
Sex
Males 121 486 0.99 0.76 1.29
Females 173 690 1.00 — —
Region
Midwest 92 491 1.00 — —
East 132 328 2.12 1.56 2.87
South 31 180 0.92 0.59 1.45
West 39 177 1.17 0.77 1.78
Physician specialty at index date
Family/General practice 49 324 1.72 0.56 5.31
Pediatrics 33 298 0.90 0.29 2.83
Dermatology 140 393 3.00 0.98 9.13
Allergy 16 52 2.53 0.74 8.60
Neonatal 0 5 0.00 0.00 INF
Other 59 197 2.44 0.81 7.35
Unknown 9 22 2.31 0.99 5.35
Disease history
Presence of infectious mononucleosis 3 3 4.00 0.81 19.82
Presence of asthma 33 122 1.25 0.89 1.76
Use of asthma medication 41 127 1.35 0.92 1.99
Use of oral corticosteroids 56 130 1.92 1.35 2.73
Severe AD (among pts 0–2 years old) 7 34 3.08 2.11 4.49
Severe AD (among pts 3+ years old) 129 353
Topical steroid use at index date
Grade 1 (super potent) 20 37 2.24 1.26 4.00
Grade 2 18 72 1.04 0.60 1.79
Grade 3 4 15 1.13 0.37 3.43
Grade 4 15 70 0.89 0.50 1.58
Grade 5 7 40 0.71 0.31 1.59
Grade 6 0 5 0.00 0.00 INF
Grade 7 (least potent) 14 66 0.86 0.47 1.56
None 216 871 1.00 — —
Use of pimecrolimus at index date
Yes 5 37 0.53 0.21 1.37
No 289 1,139 1.00 — —
Table 2 continued on the following page
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During follow-up, almost half of the patients used no
medication, 40% used topical corticosteroids alone, and
12% were exposed to at least one of the topical calcineurin
inhibitors. Of those exposed to the topical calcineurin
inhibitors, 7.4% were exposed to pimecrolimus, 3.7% were
exposed to tacrolimus, and 0.9% to both agents.
A total of 294 lymphomas occurred after the index date,
81 (27.6%) in patients o20 years old. The incidence rate of
lymphoma was 81 per 100,000 person-years. The number of
cases exposed to pimecrolimus, tacrolimus and both were 14,
11, and five, respectively. The type of lymphoma could not
be specifically determined in 66% of cases. Among those that
were identified Hodgkin disease accounted for 11.2%, and a
NHL in 22.8%. B-cell NHL accounted for 4.4 and T-cell NHL
for 18.4% of all lymphoma cases. All T-cell NHL except one
were mycosis fungoides (MF) and the remaining case was
Se´zary syndrome, which is commonly grouped with MF in
the cutaneous T-cell NHL category.
OR for AD patients older than 30 years were elevated,
especially for patients older than 60 years (OR 9.7; 95% CI
4.7–19.8). The risk of lymphoma was similar in male and in
female subjects. Patients in the East region of the USA were
found to have a higher risk of lymphoma (OR 2.1; 95% CI
1.5–2.9) compared to those in the Midwest. Severe AD was
associated with an increased risk of lymphoma (OR 3.1; 95%
CI 2.1–4.5). Visits to a dermatologist or an allergist in
comparison to visits to a family physician at index date
yielded elevated OR, as was the use of oral steroids during
follow-up OR 1.9 (95% CI 1.4–2.7) or use of grade 1 (‘‘super
potent’’) topical steroids at index date OR 2.2 (95% CI
1.3–4.0).
Table 3 presents the OR (95% CI) of lymphoma per
treatment group with non-use as reference group. The results
are presented unadjusted and adjusted for age, sex, region,
medical specialty at AD diagnosis, presence of infectious
mononucleosis, use of asthma medication, oral steroid use,
and severity of AD. In the adjusted analysis, the OR for
lymphoma associated with the different treatment modalities
were: topical steroids high potency OR 1.2 (95% CI 0.8–1.8);
topical steroids low potency OR 1.1 (95% CI 0.7–1.6);
pimecrolimus OR 0.8 (95% CI 0.4–1.6), tacrolimus OR 0.8
(95% CI 0.4–1.7), and the concomitant use of topical steroids,
pimecrolimus and tacrolimus OR 1 (95% CI 0.3–4.1) (the
concomitant use of tacrolimus and pimecrolimus without
steroids had only one case in the exposed group and the OR
yielded anN result). Severe AD remained associated with an
increased risk of lymphoma (adjusted OR 2.4; 95% CI
1.5–3.8), as did use of oral steroids (adjusted OR 1.5; 95% CI
1.0–2.4). High exposure to topical medications (topical
steroids and/or topical calcineurin inhibitors remained
associated with an increased risk of lymphoma (OR 2.30;
95% CI 1.17–4.51)).
In order to study the effect of duration of therapy on the
relationship between treatment and lymphoma, and to avoid
any risk of overmatching we repeated the analyses without
matching cases and controls but adjusting for length of
follow-up in a logistic regression model. We repeated the
stratified analysis using unconditional logistic regression and
including length of follow-up as a confounding variable. The
results were comparable to the matched results (data not
shown). The risk of lymphoma increased with the length of
follow-up as may be expected. Therefore we accepted the
matched results.
DISCUSSION
The incidence rate of lymphoma was 81 per 100,000 person-
years. This figure is compatible with an approximately 2.5-
fold increase in risk in AD patients reported by other authors
(So¨derberg et al., 2004; Zhang et al., 2004). This study did not
find an increased risk of lymphoma among users of topical
calcineurin inhibitors. However, this finding should be
confirmed when longer exposures to these drugs are
available. The increase in risk associated with topical steroids
disappeared in the adjusted analysis and the OR was slightly
greater than one only in patients exposed to ‘‘high potency’’
topical steroids. This finding is difficult to interpret but,
together with the higher OR observed for topical calcineurin
inhibitors with concomitant use of topical steroids compared
Table 2. continued
Characteristics of the study subjects Cases Controls OR 95% CI
Use of tacrolimus at index date
Yes 1 20 0.20 0.03 1.49
No 293 1,156 1.00 — —
Exposure category
Not exposed 123 584 1.00 — —
Low (among pts 0–2 years old) 10 88 1.27 0.97 1.66
Low (among pts 3+ years old) 137 474
High (among pts 0–2 years old) 1 0 4.16 2.29 7.56
High (among pts 3+ years old) 23 30
AD, atopic dermatitis; CI, confidence interval; INF, interferon; OR, odds ratio; pts, patients.
1Patients were coded as seeing specialists based on their AD claims on their index date. Patients who see more than one specialist will be coded to more than
one specialty. Thus the total number cases may be 4294.
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to topical calcineurin inhibitors alone, as well as the
increased risk observed with oral steroids use suggests that
further investigation of the relation between topical steroids
and the occurrence of lymphoma in patients with AD may
also be warranted. The use of systemic corticosteroids has
previously been associated with an increased risk of
lymphoma (Kato et al., 2002; Sorensen et al., 2004; Zhang
et al., 2004), although other studies have not shown an
increase (Beiderbeck et al., 2003; Holly and Bracci, 2003;
Askling et al., 2005).
Severity of AD was associated with a 3-fold increase in the
risk of lymphoma. Although other factors related to severity
may play a role in this increased risk, the finding is consistent
with the fact that other severe forms of chronic inflammatory
diseases, such as rheumatoid arthritis and psoriasis, are
associated with an increased risk of lymphoma (Margolis
et al., 2001; Mariette et al., 2002; Gelfand et al., 2003). In the
univariate analysis, high exposure category had an OR of
4.16 versus the non-exposed (95% CI 2.29–7.56), and severe
AD had an OR of 3.08 (95% CI 2.11–4.49). It is virtually
impossible to disentangle the effects of severity of disease on
outcome versus the true effects of drugs. However, in the
adjusted analysis, that included severity and drug exposure,
including topical steroids, in the same model, only severity of
AD remained associated with a 3-fold increase in the risk of
lymphoma.
It is possible that misclassification of cases or surveillance
bias are partially responsible for the increased risk found in
patients with severe AD. The high proportion of MF among
cases makes misclassification a plausible hypothesis. MF and
Se´zary syndrome can present with cutaneous manifestations
that resemble chronic severe adult AD (Hagstromer et al.,
2005) and it is possible that some of the cases diagnosed as
AD with ensuing MF were in fact MF cases that had been
misdiagnosed as AD. This is suggested by the high prevalence
of MF among patients with very short (1–2 days) or short (o60
days) latency between index date and diagnosis of lymphoma
(40–50% of all cases with very short latency were MF). It is
also possible that severe cases were under the care of
dermatologists and would be biopsied more frequently. The
final analysis included any cases of lymphoma developing
after the index date. Rather than applying an arbitrary
Table 3. Exposure to medication and risk of lymphoma
Cases Controls Unadjusted Adjusted
1
Medication N=294 N=1,176 OR 95% CI OR 95% CI
Exposure to medication and risk of lymphoma (all cases)
Non-use 131 603 1.00 1.00
Top corticosteroids (high potency) 72 195 1.81 1.27 2.56 1.23 0.83 1.84
Top corticosteroids (low potency) 61 263 1.09 0.78 1.53 1.06 0.72 1.57
Pimecrolimus 14 65 0.99 0.54 1.82 0.82 0.42 1.61
Pimecrolimus with TS 9 27 1.62 0.73 3.57 1.09 0.45 2.64
Pimecrolimus without TS 5 38 0.60 0.23 1.55 0.60 0.21 1.69
Tacrolimus 11 41 1.24 0.62 2.47 0.79 0.37 1.71
Tacrolimus with TS 9 28 1.54 0.71 3.32 0.93 0.39 2.22
Tacrolimus without TS 2 13 0.66 0.14 3.02 0.50 0.10 2.53
Pimecrolimus+Tacrolimus with TS 4 9 2.09 0.64 6.88 1.01 0.25 4.12
Pimecrolimus+Tacrolimus without TS 1 0 INF 0.00 INF INF 0.00 INF
Cases Controls Unadjusted Adjusted1
Medication N=241 N=964 OR 95% CI OR 95% CI
Exposure to medication and risk of lymphoma (ignoring MF/T cell cases)
Non-use 111 481 1.00 1.00
Top corticosteroids (high potency) 57 161 1.61 1.09 2.37 1.12 0.72 1.74
Top corticosteroids (low potency) 53 220 1.06 0.74 1.53 1.05 0.70 1.59
Pimecrolimus 10 59 0.73 0.36 1.47 0.65 0.31 1.38
Pimecrolimus with TS 5 24 0.94 0.35 2.56 0.77 0.26 2.25
Pimecrolimus without TS 5 35 0.61 0.24 1.59 0.57 0.20 1.60
Tacrolimus 8 36 0.98 0.44 2.15 0.71 0.30 1.69
Tacrolimus with TS 6 24 1.14 0.46 2.85 0.80 0.29 2.18
Tacrolimus without TS 2 12 0.69 0.15 3.20 0.55 0.11 2.79
Pimecrolimus+Tacrolimus with TS 1 7 0.65 0.08 5.33 0.34 0.04 3.26
Pimecrolimus+Tacrolimus without TS 1 0 INF 0.00 INF INF 0.00 INF
AD, atopic dermatitis; CI, confidence interval; INF, interferon; TS, topical steroids.
1Adjusted for sex, age, region, specialty, presence of infectious mononucleosis, asthma diagnosis, asthma drug use, oral steroid use, and severity of AD.
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threshold for making the latency time between exposure and
lymphoma development plausible, we included all cases
regarding their latency time. We repeated the analysis
including only patients with at least 60 days of follow-up
and the results were essentially unchanged (data not shown).
If topical immunomodulatory agents were to increase the
risk of lymphoma it would be secondary to systemic
immunosuppression. The most common presentation of
lymphoma associated with systemic immunosuppression is
a diffuse large cell B-cell NHL that is Epstein–Barr virus
related and occurs relatively early in the first year (often the
first 6 months) after solid organ transplantation (Swinnen,
2001; Faye and Vilmer, 2005; Ghobrial et al., 2005). Only
one case, a Burkitt’s NHL, fitting this pathologic description is
reported here and that case occurred 331 days after initiation
of topical steroids alone. The remaining cases of B-cell NHL
identified in this database are all described as chronic
lymphocytic leukemia. Chronic lymphocytic leukemia is
essentially unreported as a consequence of systemic im-
munosuppressive therapy (de Lima et al., 1998; Diehl et al.,
1999; Faye and Vilmer, 2005). In contrast among the cases
with a definite histopathologic diagnosis, cutaneous T-cell
NHL was the most frequent. Although skin T-cell lymphoma
has been reported in association with significant immuno-
suppression (Draoua et al., 2004), it is rare and tends to
present late, often after more than a year of intense
immunosuppression. The cases of MF observed in this study
occurred remarkably early during follow-up.
The main limitation of the study was the inability to
validate information obtained by record linkage in Phar-
Metrics. Therefore, we were unable to ascertain the degree of
misclassification that may have occurred. The selection of
controls was random and the hematologist who classified the
cases was blinded to treatment group, so misclassification
should be randomly distributed among the different treatment
groups. In addition, the misclassification was suspected to
mainly consist of false positive cases of MF (cases of severe
AD whose eczematoid cutaneous expression would be
misclassified as MF). Therefore, reducing misclassification
might result in a reduced OR for topical steroids but it would
be unlikely to yield higher OR with other treatment groups.
We repeated the analysis excluding the MF/T-cell NHL cases
and the results did not change (Table 3). The direction of the
minimal changes observed was either towards the null value
of the OR or a reduced risk associated with the use of topical
agents. Likewise, lack of validation did not allow studying the
relationship between different subtypes of lymphoma and
topical AD treatments.
Another limitation of the study is that information on over
the counter (OTC) drug use, including OTC topical steroids,
is lacking in PharMetrics. OTC topical steroids are of low
potency with no anticipated effect on lymphoma risk,
according to the results of this study. The prevalence of
severe AD was higher in patients receiving calcineurin
inhibitors and there was no increased risk of lymphoma
among these patients (with and without steroids). Therefore it
seems that the potential bias introduced by OTC topical
steroid use would not modify the results substantially, if at all.
The effect of missing OTC drug use in epidemiologic research
has been considered negligible in other studies (Drews and
Greenland, 1990).
Finally, this study was based on relatively small number of
cases and with relatively short follow-up and exposure times.
This was, to some extent, unavoidable given that lymphoma
is a rare disease, especially among younger patients, AD
treatment is typically intermittent and topical calcineurin
agents have been recently introduced. The case–control
design used can be conceptualized as a follow-up design in
which the person time experience of the denominators of the
incidence rate is sampled rather than measured outright. It is
also important to highlight that the selection of cases and
controls was ‘‘nested’’ in a cohort of patients with AD in
order to decrease any possible effect that this condition may
have in the risk of lymphoma.
The large sample of AD patients used is the main strength
of this study. By performing the analysis nested in a cohort of
patients with AD we decreased the possibility of confounding
by indication, detecting an increased risk of lymphoma
owing to AD itself irrespective of treatment. It is possible that
some residual confounding remains (e.g., by severity of AD).
As some of the AD patients were not being treated at the
index date it could be argued that using a more stringent
definition of AD might have yielded different results.
However, we adjusted for severity in the final model and
also repeated the analyses restricting inclusion to those
patients with prescription topical treatment of AD and the
results did not change (data not shown). The absence of
treatment at index date is not surprising. Patients with AD,
even severe, are not treated continuously for a variety of
reasons, including patients’ or parents’ fear of steroids (e.g.,
keeping fluorinated drugs off facial skin of a child), cost of
medications, desire to try emollients first, or concerns about
compliance.
This study showed no increased risk of lymphoma in
patients treated with topical calcineurin inhibitors. It is
difficult to disentangle the effects of severity of disease on
outcome versus the true effects of drugs. However, in the
adjusted analysis, severity of AD was the main factor
associated with an increased risk of lymphoma. It would be
important to confirm this finding allowing longer exposure to
these drugs in a population that allows medical validation of
cases. Likewise it would be important to evaluate the role of
severity of AD, high potency topical steroids, and oral
corticosteroids in the development of lymphoma in patients
with AD.
MATERIALS AND METHODS
The study population was derived from the PharMetrics database,
which includes data from 43 million US patients from 73 health-care
plans (http://www.pharmetrics.com/p_overview.html Last visited
March 5, 2005). Records in the PharMetrics database are represen-
tative of the USA managed care population, based on a variety of
patient and health plan demographic measures that include
geographic region, age, gender, and plan type.
We obtained all data on patients with International classification
of diseases codes 691 and 692 from July 1995 to January 2005. We
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then extracted information on all subjects with a history of AD,
indicated by the presence of an International classification of
diseases-9 CM code consistent with AD: 691.8 (dermatitis other
atopic) and 691 (dermatitis atopic) but not 691.0 (rash diaper or
napkin). We considered the index date for each patient the day a
code for AD was first present in the database.
The population included in PharMetrics consisted of 502,283
with AD. We limited inclusion in the cohort to patients with at least
6 months of enrollment in the database. We then excluded patients
with the diagnoses of lymphoma, cancer, immunosuppression,
transplantation, HIV infection and/or AIDS, use of immunosuppres-
sive agents, and anticancer drugs before the index date. After
applying these inclusion and exclusion criteria the final cohort
included 293,253 patients with AD.
Description of the AD cohort
Patients in the cohort were characterized according to the following
parameters: age, gender, specialty of the treating physician at
index date, year of entry in the cohort based on AD index date,
geographic region (East, Midwest, South, West), presence of
mononucleosis infection, or asthma during the follow-up
period, use of asthma medication and oral corticosteroids at the
index date, topical corticosteroid use at the index date, pimecroli-
mus and tacrolimus use at the index date, and severity of AD.
Severity of AD was defined based on criteria from Margolis
et al. (2001) as: patients who experienced at least four physician
visits for AD per year (for patients 3 years and older) or if they
had had at least one visit to a dermatologist in the follow-up
period (for patients younger than 3 years). Topical corticosteroid
potency was classified from grade 1 ‘‘superpotent’’ to grade 7
‘‘least potent’’ according to a modified version of the USA
National Psoriasis Foundation classification of steroid potency.
(Potencies of topical steroids. National Psoriasis Foundation.
http://www.psoriasis.org/treatment/psoriasis/steroids/potency.php?
PHPSESSID=5cb7cdba9997d740f09bb6534f791e38. Last visited on
10 January 2006.)
Cases and controls identification and characterization
Cases were identified by the presence of a code for lymphoma
(International classification of diseases codes 200, 201, 202, and
204) after the AD index date. The cases of lymphoma were reviewed
by a hematologist blinded to exposure. Cases were subdivided based
on diagnostic coding as: Hodgkin disease, NHL, and indeterminate
(meaning there was insufficient information to make a finer
distinction). NHL included B-cell NHL (specific diagnoses provided
were Burkitt’s lymphoma and chronic lymphocytic leukemia) and
T-cell NHL (specific diagnoses provided were MF and Se´zary
syndrome). Where there were simultaneous diagnoses of indetermi-
nate lymphoma and a more specific descriptor (e.g., Hodgkin
disease or MF) on the same day, only the more specific diagnosis
was recorded for classification. In one case, two diagnoses were
recorded for the same patient several years apart and two different
diagnoses were used, acknowledging the finding could be a second
malignancy.
Controls were patients from the AD cohort who did not have a
code for lymphoma at the time lymphoma was diagnosed in a
matched case. Cases and controls were matched for duration of
follow-up calculated from the index date until a lymphoma was
diagnosed in the cases according to the risk set sampling method
(Navidi and Weinhandl, 2002). For each case, four controls having
at least the same duration of follow-up were randomly selected from
the cohort of AD patients. Patients who subsequently developed
lymphoma were eligible to serve as controls until the date of their
lymphoma diagnosis. An individual could serve as a control for more
than one case.
Categorization of medication exposure
Exposure to topical AD immunomodulatory treatment was categor-
ized based both on intensity of exposure and type of medication
using National Drug Codes.
Intensity of exposure. Patients in the cohort were classified as
belonging to ‘‘no-use’’, ‘‘low’’, or ‘‘high’’ exposure categories for
topical AD prescription drugs: topical calcineurin inhibitors and
topical corticosteroids. Exposure time was estimated from the
number of days for which treatment was supplied on relevant
pharmacy claims. Patients were considered to be ‘‘persistent users’’
of pimecrolimus, and/or tacrolimus, and/or topical corticosteroids as
long as the window between two courses of therapy did not exceed
twice the number of days supplied on the previous claim. Upon not
fulfilling this persistence definition, the patient was considered
discontinued from their index therapy as of the date when the most
recent prescription in the course of therapy was ‘‘exhausted’’, this
date was deducted from the number of days for which the
medication was supplied.
Patientso3 years old were classified as high exposure users if at
least a third of their follow-up time was covered by pimecrolimus,
tacrolimus, or topical corticosteroids. Patients X3 years old were
classified as high exposure users if they had at least three
prescriptions of pimecrolimus or tacrolimus per year or they had at
least three prescriptions of topical corticosteroids classified as
potency p3 per year.
All patients having at least 1 day of their follow-up time covered
by calcineurin inhibitors or topical corticosteroid and who did not
meet the criteria for high exposure were classified as low exposure
users.
Patients who did not use a calcineurin inhibitor or a topical
corticosteroid during their follow-up time were considered ‘‘no-use’’
exposure patients.
Type of medication used: exposure group allocation. Cases
and controls were allocated to one of five mutually exclusive
exposure groups depending on the type of drug used during the
follow-up period: (1) topical steroids if there was a prescription for a
topical steroid and not for a calcineurin inhibitor, (2) pimecrolimus if
there was a prescription for pimecrolimus regardless of the presence
of a prescription for topical steroid, (3) tacrolimus if there was a
prescription for tacrolimus regardless of the presence of a prescrip-
tion for topical corticosteroid, (4) both (tacrolimus and pimecroli-
mus) if there was a prescription for pimecrolimus and tacrolimus
regardless of the presence of a prescription for topical corticosteroid,
(5) none, if there was no prescription for a topical corticosteroid or
for a topical calcineurin inhibitor. Patients classified under the
‘‘pimecrolimus’’, ‘‘tacrolimus’’, and ‘‘both’’ categories were split
into those who received concomitant topical steroids and those who
did not.
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Analysis
The relationship between exposure to medications and lymphoma
occurrence was first described in cross-tabulations. We used logistic
regression conditional on case sets with similar duration of follow-up
to calculate OR and 95% CI. We described the covariates
distribution among controls classified according to the different
levels of exposure to medications to analyze differences among
treatment groups. The final model was adjusted for all confounders
with an effect 410% on the estimate and confidence limits accrued
with all covariates in the initial model (Greenland and Rothman,
1998).
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